PMID- 21751546
OWN - NLM
STAT- MEDLINE
DCOM- 20111213
LR  - 20110714
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 30
IP  - 180
DP  - 2011 Jun
TI  - [Mechanisms of immunoglobulins activity].
PG  - 397-9
AB  - Intravenous immunoglobulin (IVIG) products are derived from plasma pools of 
      thousands of healthy donors. These immunoglobulin concentrates contain large 
      number of antibodies as well trace levels various other immunologically active 
      molecules. Therapeutic Ig formulations contain intact IgG molecules, with 
      variable amounts of monomeric and dimeric form existing in a dynamic equilibrium. 
      Paradoxically, IgG can exert both pro-and anti-inflammatory activities, depending 
      on its concentration. IVIG have been used for the treatment of primary 
      immunodeficiency disorders for more than 25 years. IVIG products are also 
      effective in the treatment of autoimmune and inflammatory disorders; however, the 
      precise mechanism (s) of action is not known. Clinical and laboratory studies 
      have documented various mechanisms of action of IVIG. The complex network of 
      immunological reactions resulting from the infusion of IVIG includes changes in 
      several cytokines, interactions with dendritic cells, T-and B-cell effects, 
      macrophage effects, mediated by distinct Fc-gamma receptors. IVIG is also a 
      recently recognized modifier of complement activation and injury. The 
      complement--scavenging ability of Ig implies expansion of the use of IVIG to all 
      disease in which generation of complement fragments plays a crucial role in 
      pathogenesis. Recent studies showed that the anti-inflammatory activity of IVIG 
      result from a minor population of the pooled IgG molecules that contains terminal 
      a-2,6 sialic acid linkages on their Fc-linked glycans. This fully processed 
      glycan is found in 1-3% of IgG in IVIG, which may explain the requirement for a 
      high dose of IVIG. Recent data demonstrate, that the anti-inflammatory properties 
      of IVIG can be recapitulated with fully recombinant preparation of appropriately 
      sialylated IgG Fc fragments. This recombinant preparation had a 35 fold enhanced 
      activity and potentially could be used at much lower doses than IVIG preparation 
      in the treatment of autoimmune disorders.
FAU - Kowalczyk, Danuta
AU  - Kowalczyk D
AD  - Zaklad Immunologii Klinicznej, Polsko-Amerykanski Instytut Pediatrii, Uniwersytet 
      Jagiellonski Collegium Medicum, Krakow. dkowalcz@cm-uj.krakow.pl
LA  - pol
PT  - Editorial
PT  - English Abstract
TT  - Mechanizmy dzialania immunoglobulin.
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Anti-Inflammatory Agents/*administration & dosage
MH  - Autoimmune Diseases/drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Immunologic Deficiency Syndromes/drug therapy
EDAT- 2011/07/15 06:00
MHDA- 2011/12/14 06:00
CRDT- 2011/07/15 06:00
PHST- 2011/07/15 06:00 [entrez]
PHST- 2011/07/15 06:00 [pubmed]
PHST- 2011/12/14 06:00 [medline]
PST - ppublish
SO  - Pol Merkur Lekarski. 2011 Jun;30(180):397-9.